{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:37:12Z","timestamp":1783489032257,"version":"3.55.0"},"reference-count":144,"publisher":"Elsevier","isbn-type":[{"value":"9780128120743","type":"print"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/bs.acc.2017.01.003","type":"book-chapter","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T06:17:11Z","timestamp":1487225831000},"page":"97-134","source":"Crossref","is-referenced-by-count":12,"title":["Measurement and Clinical Utility of \u03b2CTX in Serum and Plasma"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acc.2017.01.003_bb0005","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00223-012-9666-6","article-title":"Assessing the impact of osteoporosis on the burden of hip fractures","volume":"92","author":"Oden","year":"2013","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0010","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/annrheumdis-2013-204320","article-title":"The global burden attributable to low bone mineral density","volume":"73","author":"Sanchez-Riera","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/bs.acc.2017.01.003_bb0015","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0169-6009(91)90143-N","article-title":"Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease","volume":"8","author":"Uebelhart","year":"1990","journal-title":"Bone Miner."},{"key":"10.1016\/bs.acc.2017.01.003_bb0025","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/jbmr.5650071119","article-title":"A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine","volume":"7","author":"Hanson","year":"1992","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0030","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/clinchem\/39.4.635","article-title":"Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation","volume":"39","author":"Risteli","year":"1993","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00223-001-1034-x","article-title":"A new monoclonal antibody ELISA for detection and characterization of C-telopeptide fragments of type I collagen in urine","volume":"69","author":"Srivastava","year":"2001","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0040","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/clinchem\/40.11.2022","article-title":"Immunoassay for quantifying type I collagen degradation products in urine evaluated","volume":"40","author":"Bonde","year":"1994","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0045","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/clinchem\/42.10.1639","article-title":"Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption","volume":"42","author":"Bonde","year":"1996","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/00365519709057821","article-title":"Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA","volume":"57","author":"Fledelius","year":"1997","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/bs.acc.2017.01.003_bb0055","first-page":"193","article-title":"Specificity of the CrossLapsTM ELISA and the MAbA7 ELISA","volume":"6","author":"Fledelius","year":"1996","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0060","doi-asserted-by":"crossref","first-page":"9755","DOI":"10.1074\/jbc.272.15.9755","article-title":"Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region","volume":"272","author":"Fledelius","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0065","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1042\/bj3450473","article-title":"Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential","volume":"345","author":"Cloos","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/bs.acc.2017.01.003_bb0070","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.2002.17.5.826","article-title":"Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study","volume":"17","author":"Garnero","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0075","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1359\/jbmr.1997.12.7.1028","article-title":"Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen","volume":"12","author":"Bonde","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0080","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/clinchem\/44.11.2281","article-title":"Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen","volume":"44","author":"Rosenquist","year":"1998","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0085","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/clinchem\/48.4.671","article-title":"Serum CrossLaps: pediatric reference intervals from birth to 19 years of age","volume":"48","author":"Crofton","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0090","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/clinchem\/47.8.1410","article-title":"Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides","volume":"47","author":"Okabe","year":"2001","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0095","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/clinchem\/47.4.694","article-title":"Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis","volume":"47","author":"Garnero","year":"2001","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0100","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.clinbiochem.2013.08.018","article-title":"Measurement of C-terminal cross-linking telopeptide of type I collagen: evaluation of a new automated assay","volume":"46","author":"Huvelle","year":"2013","journal-title":"Clin. Biochem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0105","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1373\/clinchem.2008.105866","article-title":"New automated multiplex assay for bone turnover markers in osteoporosis","volume":"54","author":"Claudon","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0110","first-page":"455","article-title":"Influence of the sample matrix on the stability of beta-CTX at room temperature for 24 and 48 hours","volume":"53","author":"Lippi","year":"2007","journal-title":"Clin. Lab."},{"key":"10.1016\/bs.acc.2017.01.003_bb0115","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1515\/CCLM.2000.166","article-title":"Evaluation of a fully automated assay to measure C-telopeptide of type I collagen in serum","volume":"38","author":"Pagani","year":"2000","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2017.01.003_bb0120","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1373\/clinchem.2010.157289","article-title":"The effects of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism","volume":"57","author":"Stokes","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0125","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cccn.2004.07.024","article-title":"Serum and plasma fragments of C-telopeptides of type I collagen (CTX) are stable during storage at low temperatures for 3 years","volume":"350","author":"Qvist","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2017.01.003_bb0130","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/cs0830375","article-title":"Nyctohemeral changes in bone turnover assessed by serum bone Gla-protein concentration and urinary deoxypyridinoline excretion: effects of growth and ageing","volume":"83","author":"Eastell","year":"1992","journal-title":"Clin. Sci."},{"key":"10.1016\/bs.acc.2017.01.003_bb0135","first-page":"476","article-title":"Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women","volume":"74","author":"Schlemmer","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2017.01.003_bb0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S8756-3282(97)00225-1","article-title":"Circadian variation of urinary type I collagen crosslinked C-telopeptide and free and peptide-bound forms of pyridinium crosslinks","volume":"22","author":"Aoshima","year":"1998","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0145","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1530\/eje.0.1400332","article-title":"Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption","volume":"140","author":"Schlemmer","year":"1999","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/bs.acc.2017.01.003_bb0150","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/clinchem\/45.10.1858","article-title":"Diurnal rhythm of CrossLaps in human serum","volume":"45","author":"Wichers","year":"1999","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0155","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/clinchem\/46.3.431a","article-title":"Circadian variation in serum CrossLaps concentration is reduced in fasting individuals","volume":"46","author":"Christgau","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0160","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S8756-3282(00)00248-9","article-title":"Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy","volume":"26","author":"Christgau","year":"2000","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(02)00791-3","article-title":"Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting","volume":"31","author":"Qvist","year":"2002","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0170","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1359\/jbmr.2003.18.12.2180","article-title":"Role of gastrointestinal hormones in postprandial reduction of bone resorption","volume":"18","author":"Henriksen","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0175","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bone.2006.09.025","article-title":"Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women","volume":"40","author":"Henriksen","year":"2007","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0180","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bone.2009.07.008","article-title":"Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD","volume":"45","author":"Henriksen","year":"2009","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0185","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bone.2009.07.089","article-title":"A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy","volume":"45","author":"Rogers","year":"2009","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0190","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0195","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S8756-3282(02)00728-7","article-title":"Effect of feeding on bone turnover markers and its impact on biological variability of measurements","volume":"30","author":"Clowes","year":"2002","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0200","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/PL00005830","article-title":"Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy","volume":"66","author":"Rosen","year":"2000","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0205","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S8756-3282(00)00279-9","article-title":"Components of biological variation of biochemical markers of bone turnover in Paget's bone disease","volume":"26","author":"Alvarez","year":"2000","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0210","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1515\/cclm.2011.733","article-title":"Reference change values","volume":"50","author":"Fraser","year":"2012","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2017.01.003_bb0215","series-title":"Desirable specifications for total error, imprecision, and bias, derived from intra- and inter-individual biologic variation","author":"Ricos","year":"2014"},{"key":"10.1016\/bs.acc.2017.01.003_bb0220","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1210\/jc.2009-2516","article-title":"The effect of training status on the metabolic response of bone to an acute bout of exhaustive treadmill running","volume":"95","author":"Scott","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2017.01.003_bb0225","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1152\/japplphysiol.00764.2010","article-title":"The role of exercise intensity in the bone metabolic response to an acute bout of weight-bearing exercise","volume":"110","author":"Scott","year":"2011","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/bs.acc.2017.01.003_bb0230","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/02640414.2015.1048520","article-title":"The effects of short-term jump training on bone metabolism in females using oral contraceptives","volume":"34","author":"Reiger","year":"2016","journal-title":"J. Sports Sci."},{"key":"10.1016\/bs.acc.2017.01.003_bb0235","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00223-008-9184-8","article-title":"Physical activity and bone turnover markers: a cross-sectional and a longitudinal study","volume":"83","author":"Adami","year":"2008","journal-title":"Calcif. Tissue Int."},{"issue":"Suppl. 1","key":"10.1016\/bs.acc.2017.01.003_bb0240","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/sms.12239","article-title":"Recreational football improves bone mineral density and bone turnover marker profile in elderly men","volume":"24","author":"Helge","year":"2014","journal-title":"Scand. J. Med. Sci. Sports"},{"key":"10.1016\/bs.acc.2017.01.003_bb0245","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.injury.2010.11.017","article-title":"TRACP 5b and CTX as osteological markers of delayed fracture healing","volume":"42","author":"Moghaddam","year":"2011","journal-title":"Injury"},{"key":"10.1016\/bs.acc.2017.01.003_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2014.08.017","article-title":"Type I collagen degradation during tissue repair: comparison of mechanisms following fracture and acute coronary syndromes","volume":"69","author":"Stansfield","year":"2014","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0255","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1359\/jbmr.080703","article-title":"Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States","volume":"24","author":"Glover","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0260","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bone.2007.12.218","article-title":"Establishing a reference range for bone turnover markers in young, healthy women","volume":"42","author":"Glover","year":"2008","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0265","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bone.2010.07.017","article-title":"Reference intervals of biochemical bone turnover markers for Saudi Arabian women: a cross-sectional study","volume":"47","author":"Ardawi","year":"2010","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0270","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00223-008-9126-5","article-title":"Determinants of bone turnover markers in healthy premenopausal women","volume":"82","author":"Adami","year":"2008","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0275","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1093\/ndt\/gfp300","article-title":"Clinical significance of bone alkaline phosphatase isoforms, including the novel B1x isoform, in mild to moderate chronic kidney disease","volume":"24","author":"Haarhaus","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/bs.acc.2017.01.003_bb0280","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00198-004-1712-4","article-title":"Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients","volume":"16","author":"Okuno","year":"2005","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0285","doi-asserted-by":"crossref","first-page":"c112","DOI":"10.1159\/000081552","article-title":"Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients","volume":"98","author":"Reichel","year":"2004","journal-title":"Nephron Clin. Pract."},{"issue":"Suppl. 113","key":"10.1016\/bs.acc.2017.01.003_bb0290","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0295","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1373\/clinchem.2005.051524","article-title":"Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients","volume":"51","author":"Maeno","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0300","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S8756-3282(00)00325-2","article-title":"Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study","volume":"27","author":"Chapurlat","year":"2000","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0305","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/bonekey.2014.68","article-title":"Establishing reference intervals for bone turnover markers in healthy postmenopausal women in a nonfasting state","volume":"3","author":"Gossiel","year":"2014","journal-title":"Bonekey Rep."},{"key":"10.1016\/bs.acc.2017.01.003_bb0310","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0315","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00198-013-2439-x","article-title":"Reference intervals of bone turnover markers determined by using their curve-fitting valley for adult females in China","volume":"25","author":"Wu","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0320","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.bone.2012.02.003","article-title":"Reference intervals of bone turnover markers in healthy premenopausal women: results from a cross-sectional European study","volume":"50","author":"Eastell","year":"2012","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0325","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s00774-013-0460-y","article-title":"Study of the distribution by age group of serum cross-linked C-terminal telopeptide of type I collagen and procollagen type I N-propeptide in healthy Japanese women to establish reference values","volume":"31","author":"Nomura","year":"2013","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/bs.acc.2017.01.003_bb0330","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.bone.2007.01.008","article-title":"A cross-sectional study of bone turnover markers in healthy premenopausal women","volume":"40","author":"de Papp","year":"2007","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0335","doi-asserted-by":"crossref","first-page":"513925","DOI":"10.1155\/2013\/513925","article-title":"Establishing reference intervals for bone turnover markers in the healthy shanghai population and the relationship with bone mineral density in postmenopausal women","volume":"2013","author":"Hu","year":"2013","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/bs.acc.2017.01.003_bb0340","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bone.2013.04.003","article-title":"Age-related reference intervals for bone turnover markers from an Australian reference population","volume":"55","author":"Jenkins","year":"2013","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0345","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bone.2013.09.010","article-title":"Reference intervals for serum concentrations of three bone turnover markers for men and women","volume":"57","author":"Michelsen","year":"2013","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0350","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cca.2009.08.020","article-title":"Bone turnover markers in Spanish postmenopausal women: the Camargo cohort study","volume":"409","author":"Martinez","year":"2009","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2017.01.003_bb0355","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.cca.2010.06.010","article-title":"Bone turnover markers in Spanish adult men The Camargo Cohort Study","volume":"411","author":"Olmos","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2017.01.003_bb0360","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1210\/jc.2014-2646","article-title":"Reference intervals for bone turnover markers and their association with incident hip fractures in older men: the Health in Men study","volume":"100","author":"Chubb","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2017.01.003_bb0365","first-page":"237","article-title":"Harmonised Australian Reference Intervals for Serum PINP and CTX in Adults","volume":"35","author":"Vasikaran","year":"2014","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/bs.acc.2017.01.003_bb0370","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00198-012-2049-z","article-title":"National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges","volume":"23","author":"Bauer","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0375","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1373\/clinchem.2011.169466","article-title":"Serum concentrations of insulin-like growth factor (IGF)-1 and IGF binding protein-3 (IGFBP-3), IGF-1\/IGFBP-3 ratio, and markers of bone turnover: reference values for French children and adolescents and z-score comparability with other references","volume":"57","author":"Alberti","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0380","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.clinbiochem.2011.04.008","article-title":"Establishment of reference intervals for bone markers in children and adolescents","volume":"44","author":"Huang","year":"2011","journal-title":"Clin. Biochem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0385","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1210\/jc.2006-1706","article-title":"Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years","volume":"92","author":"Rauchenzauner","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2017.01.003_bb0390","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.clinbiochem.2015.03.002","article-title":"Comparison of results from commercial assays for plasma CTX: the need for harmonization","volume":"48","author":"Chubb","year":"2015","journal-title":"Clin. Biochem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0395","series-title":"Analytical Performance of the IDS-iSYS CrossLaps(R) Automated Immunoassay","author":"Cavalier","year":"2012"},{"key":"10.1016\/bs.acc.2017.01.003_bb0400","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1515\/cclm-2013-0934","article-title":"Method-specific differences in beta-isomerised carboxy-terminal cross-linking telopeptide of type I collagen and procollagen type I amino-terminal propeptide using two fully automated immunoassays","volume":"52","author":"Wheater","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2017.01.003_bb0405","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.clinbiochem.2015.12.002","article-title":"Comparison of clinical cut-points and treatment targets for urine NTX and plasma betaCTX-I in osteoporosis","volume":"49","author":"Chubb","year":"2016","journal-title":"Clin. Biochem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0410","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2017.01.003_bb0415","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.bone.2007.01.016","article-title":"A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density","volume":"40","author":"Saag","year":"2007","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0420","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1359\/jbmr.070617","article-title":"Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass","volume":"22","author":"Denk","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0425","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2261-10-19","article-title":"Human macrophage foam cells degrade atherosclerotic plaques through cathepsin K mediated processes","volume":"10","author":"Barascuk","year":"2010","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/bs.acc.2017.01.003_bb0430","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1210\/jc.2015-1899","article-title":"Proportion of undercarboxylated osteocalcin and serum P1NP predict incidence of myocardial infarction in older men","volume":"100","author":"Yeap","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2017.01.003_bb0435","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/CIRCHEARTFAILURE.111.962027","article-title":"The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health Study","volume":"4","author":"Barasch","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/bs.acc.2017.01.003_bb0440","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00223-014-9842-y","article-title":"A meta-analysis of reference markers of bone turnover for prediction of fracture","volume":"94","author":"Johansson","year":"2014","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0445","series-title":"Bone Turnover Marker Standardization Initiative Update","year":"2012"},{"key":"10.1016\/bs.acc.2017.01.003_bb0450","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","article-title":"Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis","volume":"94","year":"1993","journal-title":"Am. J. Med."},{"key":"10.1016\/bs.acc.2017.01.003_bb0455","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0460","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s001980050281","article-title":"An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation","volume":"11","author":"Kanis","year":"2000","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0465","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/BF01623272","article-title":"Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women","volume":"3","author":"Ross","year":"1993","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0470","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM199503233321202","article-title":"Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group","volume":"332","author":"Cummings","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2017.01.003_bb0475","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0480","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2318-11-37","article-title":"Early and late mortality in elderly patients after hip fracture: a cohort study using administrative health databases in the Lazio region, Italy","volume":"11","author":"Castronuovo","year":"2011","journal-title":"BMC Geriatr."},{"key":"10.1016\/bs.acc.2017.01.003_bb0485","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1001\/jama.298.20.2389","article-title":"Factors associated with 5-year risk of hip fracture in postmenopausal women","volume":"298","author":"Robbins","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2017.01.003_bb0490","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0495","series-title":"Bone Fracture Risk Calculator","year":"2013"},{"key":"10.1016\/bs.acc.2017.01.003_bb0500","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1359\/jbmr.090526","article-title":"Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study","volume":"24","author":"Bauer","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0505","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1210\/jc.2006-2079","article-title":"Hip and nonvertebral fracture prediction in nursing home patients: role of bone ultrasound and bone marker measurements","volume":"92","author":"Dobnig","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2017.01.003_bb0510","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","article-title":"Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study","volume":"15","author":"Garnero","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0515","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1359\/JBMR.0301244","article-title":"Biochemical markers of bone metabolism and prediction of fracture in elderly women","volume":"19","author":"Gerdhem","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0520","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1359\/JBMR.041207","article-title":"Bone resorption and osteoporotic fractures in elderly men: the Dubbo osteoporosis epidemiology study","volume":"20","author":"Meier","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0525","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0530","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study","volume":"11","author":"Garnero","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0535","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s001980200068","article-title":"Biochemical indices of bone turnover and the assessment of fracture probability","volume":"13","author":"Johnell","year":"2002","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0540","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1359\/jbmr.091006","article-title":"Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years","volume":"25","author":"Ivaska","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0545","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1359\/JBMR.041114","article-title":"Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling","volume":"20","author":"Riggs","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0550","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s00198-014-2817-z","article-title":"Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study","volume":"25","author":"Paggiosi","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0555","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2017.01.003_bb0560","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","article-title":"Five years of anti-resorptive activity after a single dose of zoledronate\u2014results from a randomized double-blind placebo-controlled trial","volume":"50","author":"Grey","year":"2012","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0565","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2017.01.003_bb0570","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters","volume":"20","author":"Arlot","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0575","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1007\/s00198-013-2379-5","article-title":"Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis","volume":"24","author":"Farahmand","year":"2013","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0580","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2017.01.003_bb0585","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1359\/jbmr.090601","article-title":"Could strontium ranelate have a synergistic role in the treatment of osteoporosis?","volume":"24","author":"Blake","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0590","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","article-title":"Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density","volume":"25","author":"Bone","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0595","doi-asserted-by":"crossref","first-page":"197S","DOI":"10.1016\/8756-3282(95)00502-1","article-title":"Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy","volume":"18","author":"Riggs","year":"1996","journal-title":"Bone"},{"key":"10.1016\/bs.acc.2017.01.003_bb0600","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","article-title":"Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis","volume":"12","author":"Bjarnason","year":"2001","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0605","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0610","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1359\/jbmr.090310","article-title":"Effects of yearly zoledronic acid 5mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis","volume":"24","author":"Delmas","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0615","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bone.2003.12.022","article-title":"Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy","volume":"34","author":"Delmas","year":"2004","journal-title":"Bone"},{"issue":"Suppl. 6","key":"10.1016\/bs.acc.2017.01.003_bb0620","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/s001980070007","article-title":"Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs","volume":"11","author":"Delmas","year":"2000","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0625","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.clinbiochem.2009.04.001","article-title":"Bone turnover markers in the management of postmenopausal osteoporosis","volume":"42","author":"Brown","year":"2009","journal-title":"Clin. Biochem."},{"key":"10.1016\/bs.acc.2017.01.003_bb0630","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1742-1241.2008.01911.x","article-title":"Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club","volume":"63","author":"Bergmann","year":"2009","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/bs.acc.2017.01.003_bb0635","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","article-title":"The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial","volume":"89","author":"Clowes","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2017.01.003_bb0640","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2006-1526","article-title":"Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis","volume":"92","author":"Delmas","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2017.01.003_bb0645","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis","volume":"20","author":"Chen","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0650","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1359\/jbmr.07090b","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis","volume":"22","author":"Eastell","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0655","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2017.01.003_bb0660","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/bs.acc.2017.01.003_bb0665","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/bs.acc.2017.01.003_bb0670","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","article-title":"Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study","volume":"174","author":"Bauer","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/bs.acc.2017.01.003_bb0675","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2014-1971","article-title":"Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?","volume":"99","author":"Cosman","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2017.01.003_bb0680","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/bs.acc.2017.01.003_bb0685","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.joms.2014.02.036","article-title":"A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study","volume":"72","author":"Hutcheson","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/bs.acc.2017.01.003_bb0690","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/bs.acc.2017.01.003_bb0695","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1210\/jc.2014-2910","article-title":"Paget's disease of bone: an Endocrine Society clinical practice guideline","volume":"99","author":"Singer","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/bs.acc.2017.01.003_bb0700","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/1055-9965.EPI-05-0492","article-title":"The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients","volume":"15","author":"Leeming","year":"2006","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/bs.acc.2017.01.003_bb0705","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2017.01.003_bb0710","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1038\/bjc.2013.270","article-title":"Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study","volume":"108","author":"de la Piedra","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2017.01.003_bb0715","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ctrv.2008.05.001","article-title":"Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/bs.acc.2017.01.003_bb0720","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.critrevonc.2011.02.005","article-title":"Consensus on the utility of bone markers in the malignant bone disease setting","volume":"80","author":"Coleman","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242317300033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242317300033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:35:34Z","timestamp":1758742534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242317300033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9780128120743"],"references-count":144,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2017.01.003","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}